News Release

RCMG Inc. (Location: 2-1-6 Sengen, Plaza Suite 106, Tsukuba, Ibaraki 305-0047, Japan) has signed a sales contract for reagents, etc. in Japan and overseas with FUJIFILM Wako Pure Chemical Corporation (Head Office Location: 1-2 Doshomachi 3-Chome, Chuo-ku, Osaka 540-8605, Japan).

■FUJIFILM Wako Pure Chemical Corporation
Company Name: FUJIFILM Wako Pure Chemical Corporation
Representative Director: President　Kazuo Shiraki
Head Office: 1-2 Doshomachi 3-Chome, Chuo-ku, Osaka 540-8605, Japan
Founded: 1922
Scope of Business: Providing laboratory chemicals, specialty chemicals and diagnostic reagents

Inquiries
RCMG Inc.
Email: marketing@medglyco.com

FUJIFILM Wako Pure Chemical Corporation
Email: ffwk-labchem-tec@fujifilm.com

News Release

Glyco-S ELISA system can measure HBsAg glycosylation of genotype A, B, C, and D.

The glycosylation of HBV is involved in HBV secretion and immune evasion. It is reasonable that the glycosylation on the envelop protein (HBsAg) affects responses of the HBV drugs related to HBV formation inhibition, immune responses, etc. RCMG’s new Glyco-S ELISA system can compare the glycosylation state of HBsAg in serum samples with the amount of S-HBsAg (qHBsAg). All HBsAg containing “a-determinant” can be applied to measure Glyco-S as shown in the figure. HBsAg of genotype A, B, C, and D expressed from CHO cells were tested by Glyco-S ELISA system.
New Contract Service: By using Glyco-S ELISA, RCMG will quantify the extent of glycosylation on HBsAg directly from your samples including clinical serum and non-clinical samples.

More detail information on this service is available at our PRODUCTS/SERVICES page.

News Release

RCMG, Inc. is pleased to announce that it has launched a new service for measuring genotype B in your samples as a Contract service [Quantifying HBsAgGi-gB].

A new antibody, HBsAgGi-gB (HB surface antigen glycan isomer of genotype B), recognizing PreS2 domain of genotype B HBsAg has been established, in addition to HBsAgGi-gC antibody specific to O-glycosylated Pre-S2 on M-HBs. HBV particles captured by HBsAgGi antibodies differ from those captured by S-HBsAg antibody. By using HBsAgG antibodies, we established new ELISA systems to measure HBV DNA- or HBV RNA-containing viral particles of genotype B and C.
By using HBsAgGi ELISA, RCMG will quantify the amount of infectious HBV containing M-HBsAg directly from your clinical or non-clinical samples.

More detail information on this service is available at our PRODUCTS/SERVICES page.

News Release

RCMG Inc. is pleased to announce that the new product [HBsAgGi ELISA Kit] to measure O-glycosylated HB surface antigen in HBV particle is launched.

In HBV patients, HBV particles consist of infectious HBV DNA particles and non-infectious particles without DNA or RNA. Non-infectious particles are mainly covered with S-HBsAg, while HBV DNA-containing particles are covered with S-, M- and L-HBsAg. HBsAgGi (HB surface antigen glycan isomer) antibody is a monoclonal antibody specific to O-glycosylated Pre-S2 on M-HBsAg. Thus, HBV particles captured by HBsAgGi differ from those captured by S-HBsAg antibody. Our proprietary HBsAgGi ELISA kit is suitable to measure HBV DNA-containing viral particles.
By using HBsAgGi ELISA Kit, you can quantify the amount of infectious HBV containing O-glycosylated M-HBsAg directly from samples including patients’ serum.
More detail information on this service is available at our PRODUCTS/SERVICES page.

News Release

RCMG Inc. is pleased to announce that the new contract service [HBsAgGi ELISA] to measure O-glycosylated HB surface antigen in HBV particle is launched.

HBsAgGi (HB surface antigen glycan isomer) is a monoclonal antibody specific to O-glycosylated Pre-S2 on M-HBs, which are predominantly present in infectious HBV particles. HBV particles captured by HBsAgGi differ from those captured by S-HBsAg antibody. By using HBsAgGi, we established for the first time a new ELISA system to measure HBV DNA-containing viral particle. Our research team also found that HBsAg ELISA can measure HBV RNA-containing viral particles after NUC treatment.
By using HBsAgGi ELISA, we will quantify the amount of infectious HBV containing O-glycosylated M-HBsAg directly from samples including patients’ serum.
New Contract Service: By using HBsAgGi ELISA, RCMG will quantify the amount of infectious HBV containing O-glycosylated M-HBsAg directly from your samples including patients’ serum.
More detail information on this service is available at our PRODUCTS/SERVICES page.

News Release

RCMG Inc. is pleased to announce that the new contract service [Glyco-S ELISA] to measure glycosylation level of HB surface antigen (HBsAg) is launched.

HBV is glycosylated by the host liver cells and secreted into blood. The glycosylation of HBV is involved in HBV formation and immune evasion. Our research team also found that the glycosylation on HBsAg affects immune responses. This time, RCMG successfully established the new proprietary ELISA system (Glyco-S ELISA) to measure and compare the glycosylation state of HBsAg in serum samples with the amount of S-HBsAg (qHBsAg).
New Contract Service: By using Glyco-S ELISA, RCMG will quantify the extent of glycosylation on S-HBsAg directly from your samples including clinical serum and non-clinical samples.
More detail information on this service is available at our Research Products/Contract Services page.

News Release

RCMG Inc. is pleased to announce that the fist paper for HBsAgGi, entitled “O-Glycosylated HBsAg peptide can induce specific antibody neutralizing HBV infection” were published in Biochimica et Biophysica Acta - General Subjects（https://pubmed.ncbi.nlm.nih.gov/34582939/） under research collaboration with National Institute of Advanced Industrial Science and Technology (AIST).

Our research team previously found that the specific glycan structure on HB surface antigen that predominantly expressed by DNA virion-containing viral particle. This time, we successfully established the new monoclonal antibody against the specific structure and demonstrated that the antibody strongly blocked HBV infection to human hepatocytes in vitro compared with clinical available HBIG (Human anti-HBs ImmunoGlobulin).

HBsAgGi (HB surface antigen glycan isomer) is a monoclonal antibody specific to O-glycosylated Pre-S2 on M-HBs, which is the specific glycan structure described above. HBsAgGi is now available for research use only and can be purchased from RCMG Inc. More detail information is available at our PROJECTS and PRODUCTS page. 

News Release

Research results in which Drs. Narimatsu (former CEO) and Angata (CEO) of our company participated were published in the journal “Oncology Letters.”
Boottanun P, Ino Y, Shimada K, Hiraoka N, Angata K, Narimatsu H. Association between the expression of core 3 synthase and survival outcomes of patients with cholangiocarcinoma.
Oncol Lett. 2021 22(5):760. doi: 10.3892/ol.2021.13021. 

News Release

Research results in which Dr. Narimatsu (CEO) and Sogabe (Researcher) of our company participated were published in the journal “Glycobiology.”
Noro E, Matsuda A, Kyoutou T, Sato T, Tomioka A, Nagai M, Sogabe M, Tsuruno C, Takahama Y, Kuno A, Tanaka Y, Kaji H, Narimatsu H. N-glycan structures of Wisteria floribunda agglutinin-positive Mac2 binding protein in the serum of patients with liver fibrosis.
Glycobiology. 2021 cwab060. doi: 10.1093/glycob/cwab060. 

News Release

RCMG has appointed Dr. Kiyohiko Angata as Chief Executive Officer. Dr. Narimatsu, previous CEO of RCMG, has been appointed as Chairman of the Board.

News Release

Research results in which Dr. Angata (CEO) of our company participated were published in the journal “Journal of Proteome Research.”
Nagai-Okatani C, Zou X, Fujita N, Sogabe I, Arakawa K, Nagai M, Angata K, Zhang Y, Aoki-Kinoshita KF, Kuno A. LM-GlycomeAtlas Ver. 2.0: An Integrated Visualization for Lectin Microarray-based Mouse Tissue Glycome Mapping Data with Lectin Histochemistry.
J Proteome Res. 2021 20(4):2069-2075. doi: 10.1021/acs.jproteome.0c00907.

News Release

Research results in which Drs. Narimatsu (CEO) and Angata (Head of R&D) of our company participated were published in the journal “PLOS ONE.”
Doi N, Ino Y, Angata K, Shimada K, Narimatsu H, Hiraoka N. Clinicopathological significance of core 3 O-glycan synthetic enzyme, β1,3-N-acetylglucosaminyltransferase 6 in pancreatic ductal adenocarcinoma.
PLoS One. 2020 15(11):e0242851. doi: 10.1371/journal.pone.0242851. 

News Release

Research results in which Dr. Angata (Head of R&D) of our company participated were presented in the conference “HUPO Connect 2020.”
Nagai-Okatani C, Zou X, Fujita N, Sogabe I, Arakawa K, Nagai M, Angata K, Zhang Y, Aoki-Kinoshita KF, Kuno A. Update on LM-GlycomeAtlas: An integrated visualization for mouse tissue glycome mapping data with lectin histochemistry.
The 19th Human Proteome Organization World Congress via WEB on 0ctober 19-20, 2020. 

News Release

Dr. Hisashi Narimatsu (CEO) of our company received ‘Dr. Kohzoh Imai Award’ at The 40th Annual Meeting of the Japan Society for Molecular Tumor Marker Research held at Hiroshima and WEB on September 30th, 2020. 

News Release

Research results in which Drs. Narimatsu (CEO) and Angata (Head of R&D) of our company participated were published in the journal “Hepatology Research.”
This study demonstrated for the first time that glycogene would be a novel therapeutic target for HBV infection by regulating HBsAg and DNA secretion from hepatocytes.
Ito K, Angata K, Kuno A, Okumura A, Sakamoto K, Inoue R, Morita N, Watashi K, Wakita T, Tanaka Y, Sugiyama M, Mizokami M, Yoneda M, Narimatsu H. Screening siRNAs against host glycosylation pathways to develop novel antiviral agents against hepatitis B virus.
Hepatol Res. 2020 50(10):1128-1140. doi: 10.1111/hepr.13552. 

News Release

Research results in which Drs. Narimatsu (CEO) and Angata (Head of R&D) of our company participated were published in the journal “Frontiers in Oncology.”
This study comprehensively evaluated the glycogene profile in human HCC cell lines through novel RNA-seq/qPCR methodology and showed the advantage of glycoprotein-based biomarker compared to traditional protein-based biomarker.
Angata K, Sawaki H, Tsujikawa S, Ocho M, Togayachi A, Narimatsu H.
Glycogene Expression Profiling of Hepatic Cells by RNA-Seq Analysis for Glyco-Biomarker Identification.
Front Oncol. 2020 10:1224. doi: 10.3389/fonc.2020.01224. 

News Release

Research results in which Drs. Narimatsu (CEO) and Angata (Head of R&D) of our company participated were published in the journal “Clinica Chimica Acta.”
Silsirivanit A, Matsuda A, Kuno A, Tsuruno C, Uenoyama Y, Seubwai W, Angata K, Teeravirote K, Wongkham C, Araki N, Takahama Y, Wongkham S, Narimatsu H. Multi-serum glycobiomarkers improves the diagnosis and prognostic prediction of cholangiocarcinoma.
Clin Chim Acta. 2020 510:142-149. doi: 10.1016/j.cca.2020.07.017. 

News Release

Research results in which Drs. Narimatsu (CEO) and Angata (Head of R&D) of our company participated were published in the journal “Nature Methods.”
Yamada I, Shiota M, Shinmachi D, Ono T, Tsuchiya S, Hosoda M, Fujita A, Aoki NP, Watanabe Y, Fujita N, Angata K, Kaji H, Narimatsu H, Okuda S, Aoki-Kinoshita KF. The GlyCosmos Portal: a unified and comprehensive web resource for the glycosciences.
Nat Methods. 2020 17(7):649-650. doi: 10.1038/s41592-020-0879-8. 

News Release

AIST and RCMG Inc. signed an exclusive licensing agreement under which RCMG Inc. will receive an exclusive license to develop and commercialize diagnostics for non-small cell lung cancer (NSCLC). 

News Release

Research results in which Dr. Narimatsu (CEO) of our company participated were published in the journal, “Journal of Proteome Research.”
Matsuda A, Kuno A, Yoshida M, Wagatsuma T, Sato T, Miyagishi M, Zhao J, Suematsu M, Kabe Y, Narimatsu H. Comparative Glycomic Analysis of Exosome Subpopulations Derived from Pancreatic Cancer Cell Lines.
J Proteome Res. 2020 19(6):2516-2524. doi: 10.1021/acs.jproteome.0c00200. 

News Release

AIST and RCMG Inc. signed an exclusive licensing agreement under which RCMG Inc. will receive an exclusive license to develop and commercialize diagnostics for small cell lung cancer (SCLC). 

News Release

AIST and RCMG Inc. signed an exclusive licensing agreement under which RCMG Inc. will receive an exclusive license to develop and commercialize HBV diagnostics worldwide. 

News Release

Research results in which Dr. Angata (Head of R&D) of our company participated were published in the journal “Molecules.”
Nagai-Okatani C, Aoki-Kinoshita KF, Kakuda S, Nagai M, Hagiwara K, Kiyohara K, Fujita N, Suzuki Y, Sato T, Angata K, Kuno A. LM-GlycomeAtlas Ver. 1.0: A Novel Visualization Tool for Lectin Microarray-Based Glycomic Profiles of Mouse Tissue Sections.
Molecules. 2019 24(16):2962. doi: 10.3390/molecules24162962. 

News Release

Dr. Narimatsu (CEO) of our company presented as a speaker at the international conference held at University of Milano in Italy.
Narimatsu H. Development of liver fibrosis diagnostics, M2BPGi, using glycoscience technologies. The 25th International Symposium on Glycoconjugate, held at Milano on August 25-31, 2019.

News Release

RCMG Inc. was certified as the technology transfer company by National Institute of Advanced Industrial Science and Technology.

News Release

RCMG Inc. launched its website.RCMG Inc. launched its website.RCMG Inc. launched its website.RCMG Inc. launched its website.

News Release

Research results in which Drs. Narimatsu (CEO) and Angata (Head of R&D) of our company participated were published in the journal “Journal of Biological Chemistry.”
Nakane T, Angata K, Sato T, Kaji H, Narimatsu H. J Biol Chem. Identification of mammalian glycoproteins with type-I LacdiNAc structures synthesized by the glycosyltransferase B3GALNT2.
2019 294(18):7433-7444. doi: 10.1074/jbc.RA118.006892. 

News Release

Research results in which Dr. Narimatsu (CEO) of our company participated were published in the journal, “Human Fertility.”
Hagiuda J, Takasaki N, Oya M, Ishikawa H, Narimatsu H. Mutation of GALNTL5 gene identified in patients diagnosed with asthenozoospermia.
Hum Fertil (Camb). 2020 23(4):226-233. doi: 10.1080/14647273.2018.1562239.

News Release

RCMG Inc. started business in Tsukuba to develop IVD and provide drug response services.RCMG Inc. started business